<em>Staphylococcus aureus costochondritis</em> and chest wall abscess in a COVID-19 patient treated with tocilizumab

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumon...

Descripción completa

Detalles Bibliográficos
Autores principales: Ergenç, İlkay, Şanal Toprak, Canan, Odabaşı, Zekaver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bayçınar Medical Publishing 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607000/
https://www.ncbi.nlm.nih.gov/pubmed/34870129
http://dx.doi.org/10.5606/tftrd.2021.8208
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.

Ejemplares similares